NewsBenzingaKeros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial Benzinga 2026.09.29 12:04 (GMT+0) Open on Benzinga Other news Why Is Snowflake Stock Surging Monday? 18 Globo Titles Heading To Netflix In Unprecedented Licensing Agreement ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment RBC Capital Maintains Outperform on Regions Financial, Lowers Price Target to $32 Wells Fargo Maintains Equal-Weight on Greif, Lowers Price Target to $88 Piper Sandler Maintains Overweight on GCM Grosvenor, Lowers Price Target to $14.5
